JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 4, 2008; DOI: 10.1124/jpet.108.143412


0022-3565/08/3273-760-769$20.00
JPET 327:760-769, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.143412v1
327/3/760    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weitl, N.
Right arrow Articles by Seifert, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weitl, N.
Right arrow Articles by Seifert, R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOPAMINE
*EPINEPHRINE

CELLULAR AND MOLECULAR

Distinct Interactions of Human β1- and β2-Adrenoceptors with Isoproterenol, Epinephrine, Norepinephrine, and Dopamine

Nina Weitl, and Roland Seifert1

Department of Pharmacology and Toxicology, School of Pharmacy, University of Regensburg, Regensburg, Germany

Fluorescence studies with purified human β2-adrenoceptor 2AR) revealed that the endogenous catecholamines, (-)-epinephrine (EPI), (-)-norepinephrine (NE), and dopamine (DOP), stabilize distinct active receptor conformations. However, the functional relevance of these ligand-specific conformations is as yet poorly understood. We addressed this question by studying fusion proteins of the β1-adrenoceptor (β1AR) and β2AR with the short and long splice variants of Gs{alpha} (Gs{alpha}S and Gs{alpha}L), respectively. Fusion proteins ensure efficient receptor/G-protein coupling and defined stoichiometry of the coupling partners. EPI, NE, DOP, and the prototypical synthetic βAR agonist, (-)-isoproterenol (ISO), showed marked differences in their efficacies at stabilizing the high-affinity ternary complex at β1AR-Gs{alpha} and β2AR-Gs{alpha} fusion proteins. Ternary complex formation was more sensitive to disruption by GTP with the β2AR than with the β1AR. Generally, in steady-state GTPase assays, ISO, EPI, and NE were full agonists, and DOP was a partial agonist. Exceptionally, at β1AR-Gs{alpha}L, NE was only a partial agonist. Generally, in adenylyl cyclase assays, ISO, EPI, and NE were full agonists, and DOP was a partial agonist. At β2AR-Gs{alpha}L, NE was only a partial agonist. There was no correlation between efficacy at stabilizing the ternary complex and activating GTPase, and there were also dissociations between Ki values for high-affinity agonist binding and EC50 values for GTPase activation. In contrast to synthetic partial agonists, DOP did not exhibit increased efficacy at βAR-Gs{alpha}L versus βAR-Gs{alpha}S fusion proteins. In conclusion, our data with βAR-Gs{alpha} fusion proteins show that endogenous catecholamines and ISO stabilize distinct conformations in the β1AR and β2AR.


Received for publication July 10, 2008
Accepted September 3, 2008.

Address correspondence to: Dr. Roland Seifert, Institute of Pharmacology, Medical School of Hannover, Carl-Neuberg-str. 1, D-30625 Hannover, Germany. E-mail: Seifert.roland{at}mh-hannover.de




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Gottle, J. Geduhn, B. Konig, A. Gille, K. Hocherl, and R. Seifert
Characterization of Mouse Heart Adenylyl Cyclase
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1156 - 1165.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Seifert and S. Dove
Functional Selectivity of GPCR Ligand Stereoisomers: New Pharmacological Opportunities
Mol. Pharmacol., January 1, 2009; 75(1): 13 - 18.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.